Kinapse Evaluates Pharma Opportunities in China

Share Article

China's pharmaceutical market is the ninth largest in the world, estimated to be worth US$19.2 billion in 2005. If projected estimates of growth are correct, China will become the world's fifth largest market by 2010 and the world's largest by 2050. These figures have compelled many global pharmaceutical companies to establish a presence in China.

Is Chinese pharma investment delivering results? What is the Chinese R&D opportunity and how can global pharmaceutical companies seize it?

These questions have been addressed in a recently published Kinapse White Paper. Commenting on the paper, Andy Black, the Kinapse Chief Executive said "This paper presents a balanced assessment of China's potential as a source of advantage to global pharmaceutical companies. Like with India and other emerging markets, there is a risk of hype overtaking reality - I believe we have taken a measured look at the opportunities, as well as the risks, and provided an insightful summary."

Shalabh Kumar, Chief Operating Officer remarked "I am pleased to release this paper as many of our clients are evaluating the relative merits of China and India for R&D operations. We have previously published a paper on opportunities for pharmaceutical companies in India, and have now brought China to the fore in this analysis. I believe the paper is strengthened by the insights brought by James Man, a Senior Analyst in our London office, and Rohit Jain, an Analyst based in India, both of whom drew upon their networks in the respective countries in completing the research".

This White Paper and others are available at http://www.kinapse.com/WhitePapers. and on request in hard copy.

About Kinapse

Kinapse provides specialist information processing services and business consulting to life sciences R&D organisations at unmatched value.

Kinapse has a novel operating model that allows it to bring together the very best people in virtual teams, in a wide range of R&D domains, committed to the success of our clients. The delivery model is differentiated from conventional R&D services companies by:

  • Blended onshore-offshore teams, tailored to client requirements;
  • Industry-veteran consulting partners who bring deep experience and expertise in specific functional areas;
  • Exclusive service partners with distinctive, complementary services.

Kinapse personnel have worked with many of the world's top pharmaceutical and biotechnology companies in consulting and information processing engagements.

Contact

James Man

W: http://www.kinapse.com
P: +44 208 946 7600

Kinapse Ltd.

Tuition House,

27-37 St George's Road,

Wimbledon,

London SW19 4EU

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

James Man
Kinapse
+44 208 946 7600
Email >